Alix de Becdelièvre

Alix de Becdelièvre

Auto-generated profile, based on publicly available information

Alix de Becdelièvre

INSERM, Unité U955, Créteil, France

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2017 in Respiratory Medicine
Verified
Journal Article
Closed access
ENElodie Nattes
Elodie Nattes
SLStephanie Lejeune
Stephanie Lejeune
ACAnia Carsin
Ania Carsin
RBRaphael Borie
Raphael Borie
IGIsabelle Gibertini
Isabelle Gibertini
RERalph Epaud
Ralph Epaud

24 January 2017 in Neurology
Verified
Journal Article
Open access
PDF file
PRPascale Richard
Pascale Richard
CTCapucine Trollet
Capucine Trollet
TSTanya Stojkovic
Tanya Stojkovic
ABAlix de Becdelievre
Alix de Becdelievre
SPSophie Perie
Sophie Perie
FFFor The Neurologists Of French Neuromuscular Reference Centers Cornemus And Filnemus
For The Neurologists Of French Neuromuscular Reference Centers Cornemus And Filnemus
Objective: Oculopharyngeal muscular dystrophy (OPMD) is an autosomal dominant adult-onset disease characterized by progressive ptosis, dysphagia, and proximal limb weakness. The genetic cause is an expanded (GCN)n mutation in the PABPN1 gene encoding for the polyadenylate-binding protein nuclear 1. We hypothesized a potential correlation between the size of the (GCN)n expansion and the severity of the phenotype. To do this, we characterized the distribution of the genotypes as well as their correlation with age at diagnosis and phenotypical features in a large cohort of heterozygous and homozygous patients with OPMD in France with a confirmed molecular diagnosis of PABPN1. Methods: We explored 354 unrelated index cases recruited between 1999 and 2014 in several neuromuscular centers in France. Results: This cohort allowed us to characterize the frequency of mutated alleles in the French population and to demonstrate a statistical correlation between the size of the expansion and the mean age at diagnosis. We also confirmed that homozygous patients present with a more severe disease. Conclusions: It has been difficult to establish phenotype–genotype correlations because of the rare nature of this disease. Our work demonstrates that patients with OPMD with longer PABPN1 expansion are on average diagnosed at an earlier age than patients with a shorter expansion, confirming that polyalanine expansion size plays a role in OPMD, with an effect on disease severity and progression.

16 October 2006 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
DDDavid Devos
David Devos
IVIsabelle Vuillaume
Isabelle Vuillaume
ABAlix De Becdelievre
Alix De Becdelievre
BMBerengère De Martinville
Berengère De Martinville
CDClaire‐Marie Dhaenens
Claire‐Marie Dhaenens
BSBernard Sablonnière
Bernard Sablonnière

7 October 2010 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
AHAlexandre Hinzpeter
Alexandre Hinzpeter
AAAbdel Aissat
Abdel Aissat
ESElvira Sondo
Elvira Sondo
CCCatherine Costa
Catherine Costa
NANicole Arous
Nicole Arous
PFPascale Fanen
Pascale Fanen
Approximately 30% of alleles causing genetic disorders generate premature termination codons (PTCs), which are usually associated with severe phenotypes. However, bypassing the deleterious stop codon can lead to a mild disease outcome. Splicing at NAGNAG tandem splice sites has been reported to result in insertion or deletion (indel) of three nucleotides. We identified such a mechanism as the origin of the mild to asymptomatic phenotype observed in cystic fibrosis patients homozygous for the E831X mutation (2623G>T) in the CFTR gene. Analyses performed on nasal epithelial cell mRNA detected three distinct isoforms, a considerably more complex situation than expected for a single nucleotide substitution. Structure-function studies and in silico analyses provided the first experimental evidence of an indel of a stop codon by alternative splicing at a NAGNAG acceptor site. In addition to contributing to proteome plasticity, alternative splicing at a NAGNAG tandem site can thus remove a disease-causing UAG stop codon. This molecular study reveals a naturally occurring mechanism where the effect of either modifier genes or epigenetic factors could be suspected. This finding is of importance for genetic counseling as well as for deciding appropriate therapeutic strategies. Mild disease outcomes associated with premature termination codons can result from at least three different mechanisms, but none of these mechanisms explain the mild phenotype observed in some patients. Subtle differences in alternative transcripts have recently been reported at NAGNAG tandem acceptor motifs, which can be detected in 30% of human genes. We provide the first experimental evidence of premature termination codon removal by alternative splicing at a NAGNAG acceptor splice site. Our study emphasizes the biological significance of such alternative splicing in the context of disease-causing mutations and defines a new phenotype-modifying mechanism that buffers nonsense mutations.

31 March 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LDLoïc Drévillon
Loïc Drévillon
GTGaëlle Tanguy
Gaëlle Tanguy
AHAlexandre Hinzpeter
Alexandre Hinzpeter
NANicole Arous
Nicole Arous
ABAlix de Becdelièvre
Alix de Becdelièvre
PFPascale Fanen
Pascale Fanen
The CFTR (cystic fibrosis transmembrane conductance regulator) protein is a large polytopic protein whose biogenesis is inefficient. To better understand the regulation of CFTR processing and trafficking, we conducted a genetic screen that identified COMMD1 as a new CFTR partner. COMMD1 is a protein associated with multiple cellular pathways, including the regulation of hepatic copper excretion, sodium uptake through interaction with ENaC (epithelial sodium channel) and NF-kappaB signaling. In this study, we show that COMMD1 interacts with CFTR in cells expressing both proteins endogenously. This interaction promotes CFTR cell surface expression as assessed by biotinylation experiments in heterologously expressing cells through regulation of CFTR ubiquitination. In summary, our data demonstrate that CFTR is protected from ubiquitination by COMMD1, which sustains CFTR expression at the plasma membrane. Thus, increasing COMMD1 expression may provide an approach to simultaneously inhibit ENaC absorption and enhance CFTR trafficking, two major issues in cystic fibrosis.

1 December 2014 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Closed access
PDF file
NDN. Deconinck
N. Deconinck
PRP. Richard
P. Richard
VAV. Allamand
V. Allamand
ABA. Behin
A. Behin
PLP. Laforet
P. Laforet
TST. Stojkovic
T. Stojkovic
Objective Mutations in one of the 3 genes encoding collagen VI (COLVI) are responsible for a group of heterogeneous phenotypes of which Bethlem myopathy (BM) represents the milder end of the spectrum. Genotype-phenotype correlations and long-term follow-up description in BM remain scarce. Methods We retrospectively evaluated the long-term clinical evolution, and genotype-phenotype correlations in 35 genetically identified BM patients (23 index cases). Results Nineteen patients showed a typical clinical picture with contractures, proximal weakness and slow disease progression while 11 presented a more severe evolution. Five patients showed an atypical presentation, namely a limb girdle muscle weakness in 2 and a congenital myopathy pattern with either no contractures, or only limited to ankles, in 3 of them. Pathogenic COL6A1-3 mutations were mostly missense or in frame exon-skipping resulting in substitutions or deletions. Twenty one different mutations were identified including 12novel ones. The mode of inheritance was, autosomal dominant in 83% of the index patients (including 17% (N=4) with a de novo mutation), recessive in 13%, and undetermined in one patient. Skipping of exon 14 of COL6A1 was found in 35% of index cases and was mostly associated with a severe clinical evolution. Missense mutations were detected in 39% of index cases and associated with milder forms of the disease. Conclusions Long-term follow-up identified important phenotypic variability in this cohort of 35 BM patients. However, worsening of the functional disability appeared typically after the age of 40 in 47% of our patients, and was frequently associated with COL6A1 exon 14 skipping.